TATamar J. van der Aart

Tamar J. van der Aart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tamar J. van der Aart has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implications of different SOFA score variants for outcome prediction in emergency department patients with an infection: a multicenter cohort study

    by Tamar J. van der Aart, Carolina Hincapié-Osorno, Isaac Santiago Arango-Gil, Konstantin Föhse, Jacobien J Hoogerwerf, Fabián Jaimes, Jacqueline Koeze, Marco van Londen, Jan C. ter Maaten, Jaap Ten Oever, et al.

  • Open Access

    Real-world clinical evaluation of the Inflammatix TriVerity test for sepsis at the emergency department: an Acutelines study

    by Michèle A. ter Voert, Jingyi Lu, Carolina Hincapié-Osorno, Tamar J. van der Aart, Sanne Ter Horst, Mehtap Ünal, Martje Visser, Raymond J. van Wijk, Jan ter Maaten, Natalie N. Whitfield, et al.

    Early sepsis recognition is challenging due to its heterogeneous presentations and limited rapid diagnostic and prognostic tools. The TriVerity TM Test, a high-multiplex host-response mRNA point-of-care test, supports clinical decision-making by estimating infection likelihood and illness severity. This study assesses TriVerity’s accuracy in Dutch emergency department (ED) patients. Adult ED patients with suspected infection and Systemic Inflammatory Response Syndrome score (SIRS) ≥2 or quick Sequential Organ Failure Assessment (qSOFA) ≥2 were prospectively included by the Acutelines data/biobank. The TriVerity test provides three scores: likelihood of bacterial infection, viral infection, and illness severity. Infection status was determined post hoc by independent physicians through clinical consensus and forced adjudication. Illness severity was defined as ICU admission or death within 7 days after ED admission. Among the 467 patients included, 234 (50%) had a bacterial infection, 80 (17%) had a viral infection, 86 (18%) had a bacterial–viral co-infection, and 67 (14%) had no infection. For bacterial infections, the TriVerity assay demonstrated a rule-in specificity of 89–94% and a rule-out sensitivity of 87–92%, depending on the adjudication method (forced vs. consensus). For viral infections, the rule-in specificity was 92–95%, and the rule-out sensitivity ranged from 76 to 92%. The illness severity score showed a rule-in specificity of 83–86% and a rule-out sensitivity of 85–87%. The TriVerity test demonstrated high specificity and sensitivity for both bacterial and viral infections, with high sensitivity and modest positive predictive value in identifying patients at risk of developing severe illness.


  • Open Access

    Renal dysfunction as a marker of adverse outcomes in early sepsis in the emergency department

    by Tamar J. van der Aart, Jan C. ter Maaten, Raymond J. van Wijk, Stephan J.L. Bakker, Hjalmar R. Bouma, Marco van Londen

    Objective Sepsis is a leading cause of acute kidney injury (sepsis-associated acute kidney injury, SA-AKI) and is associated with multiorgan failure, cardiovascular events, and increased mortality. While research has generally focused on critically ill patients in intensive care units (ICUs), most sepsis cases are managed outside the ICU. This study investigated renal dysfunction as an early risk marker in patients presenting to the emergency department (ED) with severe infection and at risk for early sepsis.Methods This post hoc analysis of patients presenting to the ED used data from the Acutelines cohort (2020–2023). Kaplan-Meier curves and univariable and multivariable Cox regression analyses were performed to assess the association between AKI and all-cause mortality, as well as in-hospital mortality and cardiovascular death, adjusting for potential confounders.Results In total, 2,045 patients presented with sepsis at the ED, of whom 246 (12%) had AKI. The overall mortality rate was 25% over a median follow-up of 346 days. AKI was associated with higher all-cause mortality (31.3% vs. 16.2%; P<0.001). After adjustment for sex, age, comorbidities, and sepsis severity, AKI remained independently associated with all-cause mortality (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.14–1.82; P=0.003), in-hospital mortality (HR, 1.65; 95% CI, 1.16–2.34; P=0.006), and cardiovascular death (HR, 2.50; 95% CI, 1.39–4.48; P=0.001). Similar outcomes were observed in a subanalysis excluding ICU patients.Conclusion SA-AKI at ED presentation is independently associated with increased all-cause, in-hospital, and cardiovascular mortality. These findings underscore the need for earlier recognition across care settings and the implementation of structured follow-up to improve patient outcomes.


  • Open Access

    Early risk assessment of severe outcomes in patients with suspected infection in the emergency department using clinical scores in a multicenter international validation

    by Carolina Hincapié-Osorno, Tamar J. van der Aart, Raymond J. van Wijk, Konstantin Föhse, Jacobien J. Hoogerwerf, Fabián Jaimes, Jacqueline Koeze, Adam Linder, Marco van Londen, Jan C. ter Maaten, et al.

  • Open Access

    Sepsis-associated acute kidney injury in mice and humans elicits heterogeneous renal microvascular microRNA responses

    by Matthijs Luxen, Tamar J. van der Aart, Rianne M. Jongman, Peter J. Zwiers, Jill Moser, Marianne Pultar, Susanna Skalicky, Andreas B. Diendorfer, Hjalmar R. Bouma, Jacqueline Koeze, et al.

    Microvascular endothelial cells play important roles in sepsis-associated acute kidney injury (SA-AKI). In this study, we focused on microvascular microRNAs changes following SA-AKI to identify microRNAs as novel druggable targets and microvasculature-related early biomarkers of SA-AKI. Using small RNA sequencing we identified 40 differentially expressed microRNAs in the renal microvasculature in response to SA-AKI. While the induction of most microRNAs was restricted to a single microvascular compartment, miR-21-5p levels were increased across the renal microvasculature in both mice and humans following SA-AKI. Functional assessment in vitro revealed that inhibition of hsa-miR-21-5p exacerbated endothelial inflammatory activation, suggesting a protective role of this microRNA in endothelial cells. Furthermore, patients with SA-AKI exhibited elevated hsa-miR-21-5p levels in plasma compared with critically ill sepsis patients without AKI. These results highlight the potential of hsa-miR-21-5p and other microRNAs as therapeutic targets and biomarkers in SA-AKI.


  • Open Access

    Validation of plasma microRNAs as biomarkers in sepsis associated acute kidney injury upon first clinical presentation reveals limited diagnostic and prognostic performance

    by Tamar J. van der Aart, Matthijs Luxen, Jacqueline Koeze, Marco van Londen, Matthias Hackl, Jan C. ter Maaten, Matijs van Meurs, Hjalmar R. Bouma, on behalf of the the Acutelines research group

    Background: Sepsis is a life-threatening response to an infection, often complicated by sepsis-associated acute kidney injury (SA-AKI). Early recognition of SA-AKI is critical but challenged by the limited sensitivity of existing diagnostic markers. MicroRNAs (miRNAs), which regulate key SA-AKI pathways, have shown diagnostic promise, yet their clinical utility in early SA-AKI recognition remains unexplored. Moreover, validation in relevant clinical settings and populations remains limited. Therefore, this study aims to explore the potential of miRNAs for early recognition of SA-AKI at emergency department (ED) presentation, and explore the generalizability of findings by including a cohort of intensive care urine (ICU) patients with more advanced disease. Methods: We conducted a post-hoc analysis of prospectively collected data from patients admitted to the ED and ICU. We performed a thorough literature review to select twelve miRNAs, previously implicated in kidney injury and sepsis or SA-AKI. MiRNAs were extracted from plasma and quantified using qPCR with and normalization to the global mean. We measured plasma levels of selected miRNAs upon ED arrival in 193 acutely ill patients (no infection, n = 65; sepsis, n = 67; SA-AKI, n = 61), and 47 critically ill patients (sepsis, n = 18; SA-AKI, n = 29). Statistical analyses included logistic and Cox regression adjusted for clinical variables, with correlations assessed between miRNA levels and disease severity markers. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: MiR-21-5p (OR 2.28, 95% CI [1.40–3.73]; p < 0.01) and miR-16-5p (OR 0.74, 95% CI [0.59–0.93]; p = 0.01) levels were associated with SA-AKI at ED presentation. Furthermore, miR-21-5p was independently associated with 30-day mortality after adjusting for age, illness severity, and comorbidities (adjusted OR 2.30, 95% CI [1.38–3.86]; p < 0.01). Similarly, in the ICU cohort with more advanced sepsis, miR-21-5p was associated with SA-AKI (OR 3.48, 95% CI [1.27–9.53]; P = 0.02), achieving an AUC of 0.74 (95% CI [0.58–0.89]), although it was not associated with 30-day mortality in this cohort. Conclusion: We selected twelve miRNAs through literature review associated with kidney injury, sepsis or SA-AKI. Of these, only miR-21-5p was associated with SA-AKI and predicted 30-day mortality upon ED admission. This analysis effectively serves as a negative validation for most literature-derived miRNAs, challenging their clinical applicability identification of SA-AKI both at early presentation and in more advanced stages. Trial registration: This study is embedded in the Acutelines data-biobank (www.acutelines.nl), registered in Clinicaltrials.gov (NCT04615065, November 3rd 2020) and the The Biobank Intensive Care Groningen registered in Clinicaltrials.gov (NCT04502511, August 6th 2020).


  • Open Access

    Uncovering molecular markers of the microvascular endothelial response in sepsis-associated acute kidney injury: a translational study in mice and humans

    by T. J. van der Aart, G. Molema, R. M. Jongman, H. R. Bouma, J. Koeze, J. Moser, M. van Londen, M. Hackl, A. B. Diendorfer, J. C. ter Maaten, et al.

    Introduction: Endothelial cells play a central role in the pathophysiology of sepsis-associated acute kidney injury (SA-AKI), yet we have limited understanding of the markers of microvascular-specific response. We therefore employed a translational approach integrating spatially resolved transcriptomics in a mouse SA-AKI model with validation in human kidney tissues and plasma, aiming to define the molecular signature of the endothelial response to SA-AKI in mice and in human patients. Methods: In this post hoc analysis of prospectively collected data, we identified sepsis-associated target mRNAs and validated their expression via RT-qPCR in distinct renal microvascular compartments isolated by laser microdissection (LMD) from both cecal ligation and puncture (CLP) mice and post-mortem kidney biopsies of SA-AKI patients. Additionally, we measured the corresponding circulating proteins in plasma from two patient cohorts with sepsis and SA-AKI: one consisting of patients presenting to the emergency department, and the other of patients with severe sepsis requiring organ support in the ICU. Results: We identified several differentially expressed genes in the renal microvasculature following sepsis, including Mt1, Mt2, Saa3, Hp, C3, Sparc, Mmp8, and Chil3. Whole-organ samples from CLP mice also showed increased expression in the liver and lung. Except for SPARC, all genes were similarly upregulated in human kidney biopsies from SA-AKI patients. Circulating protein levels were elevated in sepsis and SA-AKI patients compared to controls; however, only CHI3L1 and MMP8 showed significantly higher levels in SA-AKI versus sepsis across both early and advanced stages. Conclusion: Our findings reveal markers of the microvascular response to sepsis, which include increased levels of HP, C3, Chil3/CHI3L1, and MMP8, both at the transcriptomic level in mouse and human kidney microvasculature and at the protein level in circulating plasma of SA-AKI patients. The upregulation of these markers was shared across multiple organs and may reflect widespread endothelial activation contributing to sepsis pathophysiology.